Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer-Reference-Cited by-同舟云学术

Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer

Published:2019-03-30 Issue: Volume: Page:
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Elgendy Mohamed¹²,Fusco Juan Pablo³⁴,Segura Victor⁵,Lozano Maria Dolores⁴⁶⁷,Minucci Saverio¹⁸,Echeveste Jose Ignacio⁴⁶,Gurpide Alfonso³⁴,Andueza Mapi³⁴,Melero Ignacio⁴⁷⁹,Sanmamed Miguel F.³⁴,Ruiz Maria Rodriguez³⁴,Calvo Alfonso⁴¹⁰^ORCID,Pascual Juan Ignacio⁴¹¹,Velis Jose María⁴¹¹,Miñana Bernardino⁴¹¹,Valle Ricardo Diez⁴¹²,Pio Ruben⁴⁷¹³,Agorreta Jackeline⁴⁷¹³,Abengozar Marta⁴⁶,Colecchia Maurizio¹⁴,Brich Silvia¹⁴,Renne Salvatore Lorenzo¹⁴,Guruceaga Elisabet⁵,Patiño‐García Ana⁴¹³¹⁵,Perez‐Gracia Jose Luis³⁴⁷^ORCID

Affiliation:

1. Department of Experimental OncologyEuropean Institute of Oncology (IEO) Milan Italy

2. Department of Pharmaceutical ChemistryUniversity of Vienna Vienna Austria

3. Department of OncologyClinica Universidad de Navarra Pamplona Spain

4. Health Research Institute of Navarra (IDISNA) Pamplona Spain

5. Bioinformatics Unit, Center for Applied Medical Research (CIMA), IDISNAUniversity of Navarra Pamplona Spain

6. Pathology DepartmentClinica Universidad de Navarra Pamplona Spain

7. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain

8. Department of BiosciencesUniversity of Milan Milan Italy

9. Department of ImmunologyCenter for Applied Medical Research (CIMA) Pamplona Spain

10. Department of Histology and PathologySchool of Medicine, University of Navarra Pamplona Spain

11. Department of UrologyClinica Universidad de Navarra Pamplona Spain

12. Department of NeurosurgeryUniversity Clinic of Navarra Pamplona Spain

13. Program in Solid TumorsCenter for Applied Medical Research (CIMA) Pamplona Spain

14. Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCSIstituto Nazionale dei Tumori Milan Italy

15. Department of Pediatrics and Clinical GeneticsClinica Universidad de Navarra Pamplona Spain

Funder

Pfizer

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32256

Reference31 articles.

1. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

2. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient

3. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

4. EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

5. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High MICAL-L2 promotes cancer progression and drug resistance of renal clear cell carcinoma cell via stabilization of ACTN4 and following vimentin expression;2024-06-25

2. Molecular and functional characterization of reversible‐sunitinib‐tolerance state in human renal cell carcinoma;Journal of Cellular and Molecular Medicine;2024-05

3. The role of RNA-modifying proteins in renal cell carcinoma;Cell Death & Disease;2024-03-19

4. Nesprin1 Deficiency Is Associated with Poor Prognosis of Renal Cell Carcinoma and Resistance to Sunitinib Treatment;Oncology;2024-03-05

5. Identification of genomic drivers for the therapeutic response of Cabozantinib in patients with metastatic renal cell carcinoma;World Journal of Urology;2024-02-22